Improving surveillance for Barrett's oesophagus: AspECT and BOSS trials provide an evidence baseBMJ 2006; 332 doi: https://doi.org/10.1136/bmj.332.7556.1512 (Published 22 June 2006) Cite this as: BMJ 2006;332:1512
- Janusz Jankowski, chief investigator, AspECT trial (firstname.lastname@example.org),
- Hugh Barr, chief investigator, BOSS trial
- Department of Clinical Pharmacology, University of Oxford, Oxford OX2 6HE
- Department of Surgery, Gloucestershire Royal Hospital, Gloucester GL1 3NN
EDITOR—We read with interest the quality improvement report for improving surveillance for Barrett's oesophagus by Bampton et al.1 Improving adherence to guidelines that are themselves lacking a sufficient evidence base may not actually improve hard clinical outcomes such as all causes of mortality or even cancer progression.
The major problem with a surveillance only approach is that only an estimated 5-10% of patients with Barrett's oesophagus …